ABBVIE

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma

Phase 1

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Eftozanermin alfa
Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2020-09-30

Last Posted Date: 2024-08-14

Lead Sponsor: AbbVie

Target Recruit Count: 40

Registration Number: NCT04570631

Locations: 🇫🇷
CHRU Lille - Hopital Claude Huriez /ID# 222302, Lille, Nord, France
🇫🇷
Institut Gustave Roussy /ID# 223951, Villejuif Cedex, Val-de-Marne, France
🇺🇸
Norton Healthcare Pavilion /ID# 222918, Louisville, Kentucky, United States

and more 16 locations

RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) Without Center Involved-Diabetic Macular Edema (CI-DME)

Phase 2

Recruiting

Conditions: Diabetic Retinopathy (DR)

Interventions: Genetic: RGX-314 Dose 1
Genetic: RGX-314 Dose 2
Genetic: RGX-314 Dose 3
Drug: Topical Steroid

First Posted Date: 2020-09-28

Last Posted Date: 2023-05-22

Lead Sponsor: AbbVie

Target Recruit Count: 100

Registration Number: NCT04567550

Locations: 🇺🇸
Cumberland Valley Retina Consultants, Hagerstown, Maryland, United States
🇺🇸
Vision Research Center Eye Associates of New Mexico, Albuquerque, New Mexico, United States
🇺🇸
Retina-Vitreous Associates Medical Group, Beverly Hills, California, United States

and more 17 locations

Study to Assess Adverse Events and How Intravenous (IV) or Subcutaneous (SC) ABBV-382 Moves Through the Body of Adult Participants With Human Immuno-Deficiency Virus (HIV-1)

Phase 1

Completed

Conditions: Human Immunodeficiency Virus (HIV)

Interventions: Drug: ABBV-382
Drug: Placebo for ABBV-382

First Posted Date: 2020-09-18

Last Posted Date: 2024-03-04

Lead Sponsor: AbbVie

Target Recruit Count: 54

Registration Number: NCT04554966

Locations: 🇵🇷
Clinical Research Puerto Rico /ID# 223923, San Juan, Puerto Rico
🇺🇸
Central Texas Clinical Research /ID# 223378, Austin, Texas, United States
🇵🇷
Ponce Medical School Foundation /ID# 224231, Ponce, Puerto Rico

and more 18 locations

A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis

Recruiting

Conditions: Ankylosing Spondylitis (AS)
Rheumatoid Arthritis (RA)
Psoriatic Arthritis (PsA)
Atopic Dermatitis (AD)

First Posted Date: 2020-09-09

Last Posted Date: 2024-12-13

Lead Sponsor: AbbVie

Target Recruit Count: 3600

Registration Number: NCT04541810

Locations: 🇰🇷
Inje University - Busan Paik Hospital /ID# 259143, Busan, Busan Gwang Yeogsi, Korea, Republic of
🇰🇷
Kyungpook National University Hospital /ID# 251294, 중구, Daegu Gwang Yeogsi, Korea, Republic of
🇰🇷
Kyungpook National University Hospital /ID# 251305, 중구, Daegu Gwang Yeogsi, Korea, Republic of

and more 113 locations

Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)

Phase 3

Active, not recruiting

Conditions: Crohn's Disease (CD)

Interventions: Drug: Ustekinumab
Drug: Risankizumab

First Posted Date: 2020-08-24

Last Posted Date: 2024-06-18

Lead Sponsor: AbbVie

Target Recruit Count: 527

Registration Number: NCT04524611

Locations: 🇪🇸
Hospital Universitario Virgen Macarena /ID# 223315, Sevilla, Spain
🇪🇸
Hospital Clinico Universitario de Valencia /ID# 223321, Valencia, Spain
🇨🇦
Axler, Toronto, ON. Canada /ID# 223740, Toronto, Ontario, Canada

and more 297 locations

RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) (AAVIATE)

Phase 2

Recruiting

Conditions: Neovascular Age-Related Macular Degeneration (nAMD)

Interventions: Genetic: RGX-314 Dose 3
Genetic: RGX-314 Dose 1
Genetic: RGX-314 Dose 2
Biological: Ranibizumab
Drug: Local Steroid
Drug: Topical Steroid

First Posted Date: 2020-08-17

Last Posted Date: 2024-06-27

Lead Sponsor: AbbVie

Target Recruit Count: 115

Registration Number: NCT04514653

Locations: 🇺🇸
Bakersfield Location, Bakersfield, California, United States
🇺🇸
Baltimore Location, Baltimore, Maryland, United States
🇺🇸
Boston Location, Boston, Massachusetts, United States

and more 12 locations

A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML)

Phase 3

Completed

Conditions: Acute Myeloid Leukemia (AML)

Interventions: Drug: Venetoclax
Drug: Cytarabine

First Posted Date: 2020-08-12

Last Posted Date: 2022-05-05

Lead Sponsor: AbbVie

Target Recruit Count: 14

Registration Number: NCT04509622

Locations: 🇯🇵
NTT Medical Center Tokyo /ID# 223574, Shinagawa-ku, Tokyo, Japan
🇯🇵
Okayama University Hospital /ID# 222990, Okayama-shi, Okayama, Japan
🇯🇵
NHO Nagoya Medical Center /ID# 223671, Nagoya-shi, Aichi, Japan

and more 13 locations

AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension

Phase 1

Recruiting

Conditions: Ocular Hypertension
Open-angle Glaucoma

Interventions: Drug: AGN-193408 SR
Other: Lumigan
Other: Sham Administration
Other: Lumigan Vehicle

First Posted Date: 2020-08-05

Last Posted Date: 2024-12-09

Lead Sponsor: AbbVie

Target Recruit Count: 96

Registration Number: NCT04499248

Locations: 🇯🇵
National Hospital Organization Saitama Hospital /ID# 266953, Wako, Saitama, Japan
🇺🇸
Walman Eye Center /ID# 252153, Sun City, Arizona, United States
🇺🇸
Global Research Management /ID# 241699, Glendale, California, United States

and more 36 locations

Study to Assess Participant/Caregiver/Investigator Satisfaction of Video-Assisted Telenursing in Adult Participants With Parkinson's Disease Treated With Levodopa-Carbidopa Intestinal Gel

Completed

Conditions: Parkinson's Disease

First Posted Date: 2020-08-05

Last Posted Date: 2023-02-02

Lead Sponsor: AbbVie

Target Recruit Count: 41

Registration Number: NCT04500106

Locations: 🇮🇱
The Chaim Sheba Medical Center /ID# 222470, Ramat Gan, Tel-Aviv, Israel
🇮🇱
Kaplan Medical Center /ID# 222753, Rehovot, Israel
🇦🇺
Kingston Centre /ID# 222563, Cheltenham, Victoria, Australia

and more 10 locations

A Study of Oral Upadacitinib Tablets to Assess Treatment Patterns, Achievement of Treatment Targets and Maintenance of Response in Adult Participants With Moderate to Severe Rheumatoid Arthritis

Completed

Conditions: Rheumatoid Arthritis (RA)

First Posted Date: 2020-08-04

Last Posted Date: 2024-06-07

Lead Sponsor: AbbVie

Target Recruit Count: 1532

Registration Number: NCT04497597

Locations: 🇮🇱
Hillel Yaffe Medical Center /ID# 222170, Hadera, H_efa, Israel
🇮🇱
Rambam Health Care Campus /ID# 222118, Haifa, H_efa, Israel
🇮🇱
Galilee Medical Center /ID# 222113, Nahariya, HaTsafon, Israel

and more 260 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy